Acid Pepsin Barrier
Acid Pepsin Barrier - Related Videos
09:23
Improved Method for the Establishment of an In Vitro Blood-Brain Barrier Model Based on Porcine Brain Endothelial Cells
0 Views •
Cited by 31 •
2017
The aim of the protocol is to present an optimized procedure for the establishment of an in vitro blood-brain barrier (BBB) model based on primary porcine brain endothelial cells (pBECs). The model shows high reproducibility, high tightness, and is suitable for studies of transport and intracellular trafficking in drug discovery.
01:25
Physiological Barriers
0 Views •
2023
Physiological barriers are semi-permeable cellular structures restricting drug diffusion into intracellular compartments and tissues. There are six types of physiological barriers: blood endothelial, cell membrane, blood-brain, blood-cerebrospinal fluid (CSF), blood-placenta, and blood-testis barriers. The blood endothelial barrier is the most porous of these. It allows all small ionized, un-ionized, and lipophilic molecules to pass through the endothelial lining into the interstitial space...
06:03
Quantification of Endothelial Fatty Acid Uptake using Fluorescent Fatty Acid Analogs
0 Views •
2025
This protocol details an in vitro assay for measuring cellular lipid uptake in endothelial cells upon stimulation with BODIPY-C12 and BODIPY-C16 fluorescent analogs of long-chain and very long-chain saturated fatty acids. This method is efficient and adaptable to other cell types, offering a useful approach for studying lipid metabolism.
10:14
Using Adeno-associated Virus as a Tool to Study Retinal Barriers in Disease
0 Views •
Cited by 6 •
2015
To investigate the blood-retinal barrier permeability and the inner limiting membrane integrity in animal models of retinal disease, we used several adeno-associated virus (AAV) variants as tools to label retinal neurons and glia. Virus mediated reporter gene expression is then used as an indicator of retinal barrier permeability.
03:01
Assessing Blood-Brain Barrier Integrity in a Laser-Induced Brain Injury Rat Model
0 Views •
2025
Source: Kuts, R. et al. Laser-Induced Brain Injury in the Motor Cortex of Rats. J. Vis. Exp. (2020)This video demonstrates assessing blood-brain barrier (BBB) integrity following laser-induced brain injury in rats. A tracking dye is injected into the tail vein, allowing it to circulate to the brain and leak into the tissue through the damaged BBB. The brain is then extracted and processed to release the dye. The fluorescence intensity of the dye is measured to quantify the extent of...
FAQs
Intact epithelial tight junctions help prevent luminal acid from moving into deeper mucosal tissue. When these junctions lose integrity, acid can back-diffuse more readily, increasing local injury and inflammation. This mechanism explains why epithelial continuity is a critical pharmacologic target when considering treatments intended to reduce damage or support mucosal repair.
The surface mucus layer creates a physical boundary between gastric contents and the epithelium, while bicarbonate within that layer helps neutralize acid near the cellular surface. Their combined action limits exposure of epithelial cells to harsh luminal conditions. If either protection becomes inadequate, acid and pepsin can act closer to vulnerable tissue.
Adequate mucosal blood flow supports the local protective environment that limits injury from acid and pepsin. Along with mucus, bicarbonate, and epithelial integrity, circulation contributes to maintaining barrier function and recovery after damage. Reduced support from this system can favor persistent mucosal injury, making blood flow relevant to the progression and healing of erosions or ulcers.
Rapid epithelial cell renewal helps replace cells affected by chemical or enzymatic injury, preserving the continuity of the mucosal surface. This regenerative component complements tight junctions and surface secretions rather than replacing them. In pharmacology, it helps explain why restoring barrier function is important not only for limiting new injury but also for supporting healing.
The barrier provides a framework for relating ulcer injury to two therapeutic goals: reducing aggressive exposure from gastric acid and pepsin, and strengthening or restoring mucosal defenses. Acid-suppressing drugs address the injurious environment, whereas mucosal-protective drugs support defense or repair. This distinction helps organize treatment mechanisms without treating acid reduction as the only pathway to healing.
Improved barrier function should reduce acid back-diffusion, limit peptic digestion near the epithelium, and support recovery of damaged mucosa. Clinically relevant consequences include less inflammation and fewer erosions or ulcers, although the barrier itself is assessed through its protective effects rather than through a single component. Pharmacologic evaluation therefore considers both injury control and mucosal healing.